The authors went on to demonstrate that inhibition of XPO1 using Selinexor, a clinically-relevant XPO1 inhibitor, prevented NE transformation and prolonged the effects of targeted therapies in both prostate and lung cancer xenograft models of NE transformation [56]. This evidence concerns the gene XPO1 and lung cancer.